Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of 3 Different Doses of IV Busulfan in Conditioning for Allogeneic SCT in Poor Prognosis Myeloid Malignancies
NCT01985061Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Dec 2013
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Started Dec 2013; status: completed.
02
Drugs
busulfan
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01985061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01985061.